article Open AccessTop 1% cited
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
BMC Cancer · 2011 · Vol. 11(1) · pp. 1–1
Satoshi Watanabe✉(Niigata University Medical and Dental Hospital)Junta Tanaka(Niigata University Medical and Dental Hospital)Takeshi Ota(Niigata University Medical and Dental Hospital)Rie Kondo(Niigata University Medical and Dental Hospital)Hiroshi Tanaka(Niigata University Medical and Dental Hospital)Hiroshi Kagamu(Niigata University Medical and Dental Hospital)Kosuke Ichikawa(Niigata University Medical and Dental Hospital)Jun Koshio(Niigata University Medical and Dental Hospital)Junko Baba(Niigata University Medical and Dental Hospital)Takao Miyabayashi(Niigata University Medical and Dental Hospital)Ichiei Narita(Niigata University Medical and Dental Hospital)Hirohisa Yoshizawa(Niigata University Medical and Dental Hospital)
Abstract
Our results indicate that a 2(nd) EGFR-TKI treatment can be an effective treatment option for gefitinib responders.
Lung Cancer Treatments and MutationsLung Cancer Research StudiesColorectal Cancer Treatments and StudiesGefitinibMedicineErlotinibInternal medicineLung cancerTyrosine-kinase inhibitorOncologyErlotinib HydrochlorideEpidermal growth factor receptorProgressive disease
MeSH terms
Erlotinib HydrochlorideGefitinibAgedCarcinoma, Non-Small-Cell LungDiarrheaExanthemaFemaleHumansLung NeoplasmsMaleMiddle AgedQuinazolinesRetrospective StudiesTreatment OutcomeRetreatment
Citations
392
FWCI
30.67
field-weighted impact
References
45
Percentile
100%
vs. same field & year
Citations per year
Cited by
p53 Family and Cellular Stress Responses in Cancer
Frontiers in Oncology · 2014 · 289 citations
Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence
Breast Cancer Research and Treatment · 2016 · 328 citations
References
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
PLoS Medicine · 2005 · 3,519 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Clinical Cancer Research · 2006 · 827 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2003 · 2,883 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
New England Journal of Medicine · 2009 · 8,201 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.